TNXP: Tonix Pharmaceuticals Inc. Company Value to Net Income

Corporate emblem and logo of Tonix Pharma (TNXP)

The historical price action of Tonix Pharmaceuticals (TNXP), where the indicator stands at -0.30, is driven by strict regulatory oversight and patent wars. A lack of profitable products forces the firm to raise capital through the issuance of new securities. Research stability is ensured by duplicating equipment across laboratories in Massachusetts and Maryland, which supports the company's diversified biopharmaceutical operations.

TNXP Tonix Pharmaceuticals Holding: Price to Earnings Ratio in the range 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for Tonix Pharma (TNXP)

Comprehensive company analysis:Tonix Pharmaceuticals Inc. - TNXP
Flagship merchandise of Tonix Pharmaceuticals Holding Corp.

Investors must critically evaluate the market value of Tonix Pharmaceuticals (TNXP) relative to its actual yield to minimize risks. The company's operating model relies on government grants and internal development without the involvement of external partners. By analyzing the company's fundamental P/E, you measure the ratio of market capitalization to net income, which allows for the identification of overpayment based on future expectations. This indicator determines the degree of investment attractiveness and the financial stability of the business.

Competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|Market Cap to Net Income Ratio Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Price to Earnings Ratio|Price to Earnings Ratio Tectonic Therapeutic, Inc.|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)